Tirosina quinase (Galician Wikipedia)

Analysis of information sources in references of the Wikipedia article "Tirosina quinase" in Galician language version.

refsWebsite

Global rank Galician rank

14nih.gov

4^th place

6^th place

11doi.org

2^nd place

7^th place

1niscair.res.in

low place

1archive.org

6^th place

8^th place

archive.org

Weinberg, Robert A. (2007). The Biology Of Cancer. New York: Garland Science, Taylor & Francis Group, LLC. pp. 757–759. ISBN 0-8153-4076-1.

doi.org

dx.doi.org

Hanks SK, Quinn AM, Hunter T (xullo de 1988). "The protein kinase family: conserved features and deduced phylogeny of the catalytic domains". Science 241 (4861): 42–52. PMID 3291115. doi:10.1126/science.3291115.
Radha V, Nambirajan S, Swarup G (marzo de 1996). "Association of Lyn tyrosine kinase with the nuclear matrix and cell-cycle-dependent changes in matrix-associated tyrosine kinase activity". European Journal of Biochemistry 236 (2): 352–9. PMID 8612602. doi:10.1111/j.1432-1033.1996.00352.x.
Ruetten H, Thiemermann C (September 1997). "Effects of tyrphostins and genistein on the circulatory failure and organ dysfunction caused by endotoxin in the rat: a possible role for protein tyrosine kinase". British Journal of Pharmacology 122 (1): 59–70. PMC 1564904. PMID 9298529. doi:10.1038/sj.bjp.0701345.
Schaller MD, Borgman CA, Cobb BS, Vines RR, Reynolds AB, Parsons JT (June 1992). "pp125FAK a structurally distinctive protein-tyrosine kinase associated with focal adhesions". Proceedings of the National Academy of Sciences of the United States of America 89 (11): 5192–6. PMC 49256. PMID 1594631. doi:10.1073/pnas.89.11.5192.
Dengjel J, Kratchmarova I, Blagoev B (October 2009). "Receptor tyrosine kinase signaling: a view from quantitative proteomics". Molecular bioSystems 5 (10): 1112–21. PMID 19756300. doi:10.1039/b909534a.
Wiley HS, Burke PM (January 2001). "Regulation of receptor tyrosine kinase signaling by endocytic trafficking". Traffic 2 (1): 12–8. PMID 11208164. doi:10.1034/j.1600-0854.2001.020103.x.
Silvennoinen O, Saharinen P, Paukku K, Takaluoma K, Kovanen P (July 1997). "Cytokine receptor signal transduction through Jak tyrosine kinases and Stat transcription factors". APMIS 105 (7): 497–509. PMID 9269296. doi:10.1111/j.1699-0463.1997.tb05047.x.
Gunby RH, Sala E, Tartari CJ, Puttini M, Gambacorti-Passerini C, Mologni L (November 2007). "Oncogenic fusion tyrosine kinases as molecular targets for anti-cancer therapy". Anti-Cancer Agents in Medicinal Chemistry 7 (6): 594–611. PMID 18045055. doi:10.2174/187152007784111340.
Kris MG, Natale RB, Herbst RS, Lynch TJ, Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis H, Sandler A, Albain KS, Cella D, Wolf MK, Averbuch SD, Ochs JJ, Kay AC (October 2003). "Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial". JAMA 290 (16): 2149–58. PMID 14570950. doi:10.1001/jama.290.16.2149.
Blanke CD, Demetri GD, von Mehren M, Heinrich MC, Eisenberg B, Fletcher JA, Corless CL, Fletcher CD, Roberts PJ, Heinz D, Wehre E, Nikolova Z, Joensuu H (February 2008). "Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT". Journal of Clinical Oncology 26 (4): 620–5. PMID 18235121. doi:10.1200/JCO.2007.13.4403.
le Coutre P, Ottmann OG, Giles F, Kim DW, Cortes J, Gattermann N, Apperley JF, Larson RA, Abruzzese E, O'Brien SG, Kuliczkowski K, Hochhaus A, Mahon FX, Saglio G, Gobbi M, Kwong YL, Baccarani M, Hughes T, Martinelli G, Radich JP, Zheng M, Shou Y, Kantarjian H (February 2008). "Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia". Blood 111 (4): 1834–9. PMID 18048643. doi:10.1182/blood-2007-04-083196.

nih.gov

ncbi.nlm.nih.gov

Hanks SK, Quinn AM, Hunter T (xullo de 1988). "The protein kinase family: conserved features and deduced phylogeny of the catalytic domains". Science 241 (4861): 42–52. PMID 3291115. doi:10.1126/science.3291115.
Radha V, Nambirajan S, Swarup G (marzo de 1996). "Association of Lyn tyrosine kinase with the nuclear matrix and cell-cycle-dependent changes in matrix-associated tyrosine kinase activity". European Journal of Biochemistry 236 (2): 352–9. PMID 8612602. doi:10.1111/j.1432-1033.1996.00352.x.
Ruetten H, Thiemermann C (September 1997). "Effects of tyrphostins and genistein on the circulatory failure and organ dysfunction caused by endotoxin in the rat: a possible role for protein tyrosine kinase". British Journal of Pharmacology 122 (1): 59–70. PMC 1564904. PMID 9298529. doi:10.1038/sj.bjp.0701345.
Schaller MD, Borgman CA, Cobb BS, Vines RR, Reynolds AB, Parsons JT (June 1992). "pp125FAK a structurally distinctive protein-tyrosine kinase associated with focal adhesions". Proceedings of the National Academy of Sciences of the United States of America 89 (11): 5192–6. PMC 49256. PMID 1594631. doi:10.1073/pnas.89.11.5192.
Dengjel J, Kratchmarova I, Blagoev B (October 2009). "Receptor tyrosine kinase signaling: a view from quantitative proteomics". Molecular bioSystems 5 (10): 1112–21. PMID 19756300. doi:10.1039/b909534a.
Wiley HS, Burke PM (January 2001). "Regulation of receptor tyrosine kinase signaling by endocytic trafficking". Traffic 2 (1): 12–8. PMID 11208164. doi:10.1034/j.1600-0854.2001.020103.x.
Silvennoinen O, Saharinen P, Paukku K, Takaluoma K, Kovanen P (July 1997). "Cytokine receptor signal transduction through Jak tyrosine kinases and Stat transcription factors". APMIS 105 (7): 497–509. PMID 9269296. doi:10.1111/j.1699-0463.1997.tb05047.x.
Bhise SB, Nalawade AD, Wadhawa H (December 2004). "Role of protein tyrosine kinase inhibitors in cancer therapeutics". Indian Journal of Biochemistry & Biophysics 41 (6): 273–80. PMID 22900354.
Gunby RH, Sala E, Tartari CJ, Puttini M, Gambacorti-Passerini C, Mologni L (November 2007). "Oncogenic fusion tyrosine kinases as molecular targets for anti-cancer therapy". Anti-Cancer Agents in Medicinal Chemistry 7 (6): 594–611. PMID 18045055. doi:10.2174/187152007784111340.
Palacios EH, Weiss A. Function of the Src-family kinases, Lck and Fyn, in T-cell development and activation. Oncogene. 2004 Oct 18;23(48):7990-8000. PMID 15489916 . DOI 10.1038/sj.onc.1208074 .
Kris MG, Natale RB, Herbst RS, Lynch TJ, Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis H, Sandler A, Albain KS, Cella D, Wolf MK, Averbuch SD, Ochs JJ, Kay AC (October 2003). "Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial". JAMA 290 (16): 2149–58. PMID 14570950. doi:10.1001/jama.290.16.2149.
Blanke CD, Demetri GD, von Mehren M, Heinrich MC, Eisenberg B, Fletcher JA, Corless CL, Fletcher CD, Roberts PJ, Heinz D, Wehre E, Nikolova Z, Joensuu H (February 2008). "Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT". Journal of Clinical Oncology 26 (4): 620–5. PMID 18235121. doi:10.1200/JCO.2007.13.4403.
le Coutre P, Ottmann OG, Giles F, Kim DW, Cortes J, Gattermann N, Apperley JF, Larson RA, Abruzzese E, O'Brien SG, Kuliczkowski K, Hochhaus A, Mahon FX, Saglio G, Gobbi M, Kwong YL, Baccarani M, Hughes T, Martinelli G, Radich JP, Zheng M, Shou Y, Kantarjian H (February 2008). "Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia". Blood 111 (4): 1834–9. PMID 18048643. doi:10.1182/blood-2007-04-083196.
Kuwai T, Nakamura T, Sasaki T, Kim SJ, Fan D, Villares GJ, Zigler M, Wang H, Bar-Eli M, Kerbel RS, Fidler IJ (May 2008). "Phosphorylated epidermal growth factor receptor on tumor-associated endothelial cells is a primary target for therapy with tyrosine kinase inhibitors". Neoplasia 10 (5): 489–500. PMC 2373870. PMID 18472966.

niscair.res.in

nopr.niscair.res.in

Bhise SB, Nalawade AD, Wadhawa H (December 2004). "Role of protein tyrosine kinase inhibitors in cancer therapeutics". Indian Journal of Biochemistry & Biophysics 41 (6): 273–80. PMID 22900354.